Every material Form 8-K Akari Therapeutics Plc has filed with the SEC since June 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On September 29, 2026, Akari Therapeutics amended the Chief Executive Officer Agreement with CEO Abizer Gaslightwala. The amendment raises his base salary from $475,000 to $625,000 effective August 18, 2026, increases his target bonus to 55% of base salary, and grants options on 174,000 ADSs, with parts of the package tied to shareholder approval of a plan amendment.
Base salary rises from $475,000 to $625,000, effective August 18, 2026; $62,500 of it is delivered as RSUs instead of cash over 12 months
Target annual bonus increases from 50% to 55% of base salary, for target base salary and bonus of approximately $970,000
Options to purchase 174,000 ADSs granted as of August 18, 2026, vesting monthly over four years from March 18, 2026
RSUs and option grants depend on shareholder approval of an increase to the ADSs reserved under the 2023 Plan
Akari Therapeutics reported second quarter 2026 results, with a net loss of $4.8 million, up from $1.9 million a year earlier, as research and development spending rose to $2.1 million from $0.7 million. The company raised about $8.6 million in gross financing during the quarter, and cash totaled $7.7 million as of June 30, 2026, which it says supports its AKTX-101 development toward a Phase 1 trial planned for mid-2027.
Net loss for Q2 2026 was $4.8 million, compared with $1.9 million in Q2 2025.
R&D expenses were $2.1 million, up from $0.7 million; G&A expenses were $2.5 million, flat year over year.
Financing totaled about $8.6 million gross ($5.5 million private placement plus $3.1 million from warrant exercises), or about $8.0 million net.
Cash was $7.7 million at June 30, 2026, up from $5.2 million at December 31, 2025.
Akari Therapeutics amended its securities purchase agreement on June 23, 2026, combining its second and third closings into one. On June 26, 2026, it issued the remaining 980,395 ADSs, or prefunded warrants in lieu of them, completing the private placement. Delivery of the Series H, I and J warrants depends on shareholder approval at the annual general meeting on June 30, 2026.
Offering originally covered 1,470,588 unregistered ADSs or prefunded warrants, funded in three tranches
First closing occurred May 27, 2026; the second and third closings were combined into one on June 26, 2026
Remaining 980,395 ADSs or prefunded warrants were issued on the combined closing date
Series H, I and J warrants are contingent on shareholder approval at the June 30, 2026 annual general meeting
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Akari Therapeutics Plc filing is on SEC EDGAR ↗. 8-K briefs of other companies →